Flagship Wealth Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$35.6K Hold
185
– – 0.01% 297
2026
Q2
$13K Buy
185
+25
+16% +$1.29K ﹤0.01% 387
2026
Q1
$4.42K Sell
160
-75
-32% -$3.5K ﹤0.01% 318
2025
Q4
$6.93K Hold
235
– – ﹤0.01% 340
2025
Q3
$6.07K Buy
235
+75
+47% +$2.09K ﹤0.01% 362
2025
Q2
$4.41K Hold
160
– – ﹤0.01% 334
2025
Q1
$4.54K Hold
160
– – ﹤0.01% 335
2024
Q4
$6.65K Buy
+160
New +$7.65K ﹤0.01% 312

Other funds holding MRNA

Flagship Wealth Advisors's MRNA Position: Q3 2026 in Review

Flagship Wealth Advisors held its Moderna (MRNA) position steady in Q3 2026 at 185 shares worth $35.6K. The position accounts for 0.01% of the portfolio, ranked #297.

Flagship Wealth Advisors first reported a position in MRNA in Q4 2024 and has held it in 8 quarters since. 962 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Flagship Wealth Advisors held 185 shares of Moderna worth $35.6K as of Q3 2026.
  • Flagship Wealth Advisors left its Moderna share count unchanged in Q3 2026.
  • Moderna made up 0.01% of Flagship Wealth Advisors's portfolio in Q3 2026, its #297 holding.
  • Flagship Wealth Advisors first reported a position in Moderna in Q4 2024 and has held it in 8 quarters since.
  • 962 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Flagship Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.